证券代码：002826 股票简称：易明医药 公告编号：2025-028 西藏易明西雅医药科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决议案的情形。 5、会议表决方式：现场记名书面投票与网络投票相结合。 2、本次股东大会没有涉及变更前次股东大会决议的议案。 一、会议召开情况： 1、会议通知： 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"易明医 药"）董事会于 2025 年 4 月 25 日在《证券时报》《上海证券报》和巨潮资讯 网(www.cninfo.com.cn)上刊登了《关于召开 2024 年年度股东大会的通知》 （以下简称"股东大会通知"），拟定于 2025 年 5 月 16 日召开 2024 年年股东 大会。 2、会议召开时间： （1）现场会议时间为：2025 年 5 月 16 日（星期五）下午 14:00。 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体 时间为 2025 年 5 月 16 日上午 9:15-9:25，9:30-11 ...

法律意见书 植德京(会)字[2025]0059 号 二〇二五年五月 北京植德律师事务所 关于西藏易明西雅医药科技股份有限公司 2024 年年度股东大会的 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于西藏易明西雅医药科技股份有限公司 2024 年年度股东大会的 法律意见书 植德京(会)字[2025]0059 号 致：西藏易明西雅医药科技股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法 ...

证券代码：002826 股票简称：易明医药 公告编号：2025-031 西藏易明西雅医药科技股份有限公司 关于召开 2025 年第二次股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"本公司"或"公司"）第 三届董事会第二十四次会议审议通过了《关于召开 2025 年第二次临时股东会的 议案》，定于 2025 年 6 月 4 日（星期三）下午 14:00 召开 2025 年第二次临时股 东会，现将本次会议的相关事项通知如下： 一、本次会议召开的基本情况 （一）会议届次：2025 年第二次临时股东会 （二）会议召集人：公司董事会 （三）会议召开的合法、合规性：公司第三届董事会第二十四次会议审议通 过相关议案，本次股东会会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》等的规定。 （四）会议表决方式：现场记名书面投票与网络投票相结合 （五）会议时间： 1、现场会议时间为：2025 年 6 月 4 日（星期三）下午 14:00。 2、网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-029 西藏易明西雅医药科技股份有限公司 第三届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"）第 三届董事会第二十四次会议已于 2025 年 5 月 16 日在公司会议室以现场与通讯相 结合的方式召开。本次会议于 2025 年 5 月 6 日以电子邮件方式通知了全体董事。 本次会议应到董事 7 人，实到董事 7 人。公司高级管理人员、第四届董事 会候选人列席了本次会议。会议由董事长许可先生召集和主持，公司董事会秘书 李前进出席并记录了本次会议。本次会议的召集、召开和表决程序符合《中华人 民共和国公司法》（以下简称"《公司法》"）等相关法律法规以及《公司章程》 的规定。 （3）提名李前进女士为第四届董事会非独立董事候选人。 审议结果：同意 7 票，反对 0 票，弃权 0 票。 本议案已经董事会提名委员会审议通过。 二、董事会会议审议情况 1、审议通过了《关于公司董事会换届选举非独立 ...

Group 1: Company Performance and Strategy - The company has adjusted its strategic planning to focus on self-produced products, maintaining the performance growth of its core product, Miglitol tablets, which has seen an increasing proportion of total revenue [2][5]. - The revenue from third-party cooperative products has gradually declined, leading to the termination of such collaborations [2]. - The company aims to explore the clinical value of existing products and plans to launch some dormant products, enhancing its product system through various means [2][5]. Group 2: Financial Management and Investor Relations - The company reported a profit increase for 2024, primarily due to the absence of a goodwill impairment charge of CNY 19.8 million that was recorded in 2023 [5]. - The board of directors has proposed a profit distribution plan for 2024, which will be submitted for approval at the annual shareholders' meeting [3]. - The company emphasizes the importance of rational investment and risk awareness due to the influence of macroeconomic factors on stock prices [3][6]. Group 3: Shareholder Concerns and Corporate Governance - The reduction of shares by a board member is attributed to personal financial needs, with no intention of exiting the board [1][2]. - The company has no current plans for a private placement, despite having idle funds for financial management [3]. - The management reassures investors of their confidence in the company's future development and industry prospects [3][5]. Group 4: Product Development and Market Position - The company is focused on developing core products for chronic diseases and women's health, with an emphasis on maintaining stable operations [4][5]. - The core product, Miglitol tablets, is highlighted as a key focus area for the company [7]. - The company is exploring new product introductions and partnerships to enhance its market position [5][6].

投资者可以通过以下两种方式参与：1）登录同花顺路演平台，进入直播间 https://board.10jqka.com.cn/rs/pc/detail?roadshowId=1010543 进行提问； 2）使用同花顺手机炒股软件扫描下方二维码进入路演直播间进行提问互动交流。 证券代码：002826 证券简称：易明医药 公告编号：2025-027 西藏易明西雅医药科技股份有限公司 关于举行 2024 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）已于 2025 年 04 月 25 日披露了《2024 年年度报告》。为了便于广大投资者更加全面深入地了解 公司情况，公司将于 2025 年 05 月 14 日（星期三）下午 15:00-17:00 在同花顺 路演平台采用网络远程方式举行 2024 年度业绩说明会。本次年度业绩说明会将 采取网络远程文字互动的方式举行。 出席本次年度报告说明会的人员有：董事长许可先生，董事、总经理兼财务 总监周敏女士，独立董事肖兴刚先生，副总经理、董事会秘书李前进女 ...

Market Overview - The Shanghai Composite Index closed at 3328.43 points, above the six-month moving average, with an increase of 0.37% [1] - The total trading volume of A-shares reached 12152.25 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 144 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - JinHao Medical: 26.73% - SuAo Sensor: 19.75% - HuaWu Co., Ltd.: 17.98% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Aerospace Intelligent Manufacturing - Changqing Technology - China Merchants Highway [1] Performance of Selected Stocks - JinHao Medical: Today's increase of 29.96% with a turnover rate of 23.69% [1] - SuAo Sensor: Increased by 20.05% with a turnover rate of 8.96% [1] - HuaWu Co., Ltd.: Increased by 19.94% with a turnover rate of 20.89% [1] Additional Notable Stocks - Other stocks with notable performance include: - JiuDing Investment: 9.97% increase, 7.73% turnover rate - Arrow Home: 10.02% increase, 8.27% turnover rate - Construction Industry: 10.01% increase, 13.40% turnover rate [1]

Stock Performance - Several stocks have shown significant gains, with notable performances including: - 恒天海龙 with a 10.07% increase over two days [2] - 晨曦航空 achieving a 19.96% rise on its first board [3] - 通易航天 with a remarkable 29.96% increase on its first board [3] - 新坐标 maintaining a 10.01% increase over four days [5] - 全筑股份 also showing a 10.00% increase over four days [9] Industry Trends - The robotics sector is gaining traction, with multiple companies experiencing stock price increases attributed to advancements in robotic technology and applications [4][5][7] - The AI computing industry is showing strong performance, as indicated by the positive financial results from companies in this sector, suggesting a sustained high level of industry activity [8] - The brain-computer interface (BCI) technology is gaining attention following FDA approval for Neuralink's device, which is aimed at aiding patients with severe communication disabilities [11] - The chemical industry is experiencing volatility in product prices, drawing market interest towards related companies [13] - The semiconductor industry is benefiting from increased investment and support for domestic high-end lithography machines, which is expected to boost the semiconductor equipment supply chain [16] - The real estate sector is reacting positively to the People's Bank of China's decision to lower housing loan interest rates, which is likely to stimulate market activity [18] Market Reactions - Stocks related to the ride-hailing industry are responding positively to the news of a partnership between autonomous driving company 小马智行 and Uber, with significant stock price increases observed [20][21] - The food and beverage sector is also seeing positive movements, influenced by the central bank's announcement of a new loan program aimed at boosting consumer spending [22][24] - The financial sector is reacting to the People's Bank of China's announcement of a series of monetary policy measures, including a reserve requirement ratio cut and interest rate adjustments [25][26]

Core Viewpoint - 易明医药's 2024 annual report indicates a significant increase in net profit despite a decline in revenue, highlighting the company's challenges in market competition and reliance on non-recurring gains [1][5]. Revenue Performance - In 2024, 易明医药 achieved total revenue of 6.52 billion, a decrease of 2.27% year-on-year, marking the second consecutive year of revenue decline [4]. - The revenue in 2023 was 6.67 billion, reflecting a more substantial decline of 22.14% compared to 2022 [4][2]. Profitability Analysis - The net profit attributable to 易明医药 in 2024 was 0.46 billion, representing a substantial increase of 198.50% year-on-year [1][5]. - The non-recurring net profit was 18.45 million, showing a remarkable growth of 1579.33% compared to the previous year's 1.10 million, indicating a reliance on non-operating income for profit growth [5]. Market Challenges - The decline in revenue signals significant pressure from market competition, particularly in the context of frequent policy changes and deepening centralized procurement in the pharmaceutical industry [4]. - The main product, 米格列醇片 (奥恬苹®), performed well in 2024, winning bids in 25 provinces, but other products like 蒙脱石散 (贝易平®) and 多潘立酮片 (维动啉®) did not contribute effectively to revenue growth [4]. Termination of Collaborations - 易明医药 terminated its collaboration with 上海医药 for 瓜蒌皮注射液 (新通®) in December 2024, which was a significant revenue source, leading to uncertainty in future revenue streams [6]. - The company also suspended the market supply of 盐酸纳美芬注射液 (易美芬®), further impacting its market presence [6]. Future Outlook - To address the challenges posed by the termination of collaborations and declining revenue, 易明医药 needs to enhance its investment in product development and market promotion [6]. - The company has made efforts to improve profitability through optimized production and marketing strategies, but ongoing revenue decline and competitive pressures necessitate a stronger focus on core business capabilities [6].

2024 年限制性股票激励计划预留授予激励对象名单 （授予日） 西藏易明西雅医药科技股份有限公司 3、上述合计数与各明细数直接相加之和在尾数上如有差异，系百分比结果四舍五入所 致。 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 刘小琼 | 核心管理/业务人员 | | 2 | 张海龙 | 核心管理/业务人员 | | 3 | 孙尊东 | 核心管理/业务人员 | | 4 | 宋庭芬 | 核心管理/业务人员 | | 5 | 王波 | 核心管理/业务人员 | 二、 预留授予的公司核心管理/业务人员名单 西藏易明西雅医药科技股份有限公司 董事会 二〇二五年四月二十三日 一、 预留授予的激励对象名单及拟授出权益分配情况 | 姓名 | 职务 | 获授的限制性股 票数量（万股） | 占本次预留授予 总量的比例 | 占授予时公司 股本总额的比 | | --- | --- | --- | --- | --- | | | | | | 例 | | 高瑛 | 副总经理 | 20.00 | 55.56% | 0.10% | | 姜华明 | 副总经理 | 8.00 | 22.22% | 0.04% | ...